thromboembolic events; dose-dependent improvements in blood-clotting activity support the potential of HMB-001 as a first-in-class prophylactic treatment for Glanzmann Thrombasthenia and other blood ...
Richmond Pharmacology, one of the UK’s leading first-in-human clinical trials companies, has just completed the dosing in the first cohort in Velora Pioneer, a phase 1/2 clinical trial investigating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results